Sebetralstat HCl | CAS#2163789-76-0 (HCl)| kallikrein inhibitor

MedKoo Cat#: 414718 | Name: Sebetralstat HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sebetralstat, also known as KVD-900, is a fast-acting oral PKa inhibitor that rapidly inhibits PKa activity, kallikrein kinin system activation and HK cleavage in plasma. On-demand administration of KVD900 may provide an opportunity to halt the generation of bradykinin and reverse HAE attacks. KVD900 is a selective, competitive and reversible inhibitor of human PKa enzyme with a Ki of 3.02 nM. The association constant (Kon ) of KVD900 for PKa is >10 × 106 M-1 s-1 .

Chemical Structure

Sebetralstat HCl

CAS#2163789-76-0 (HCl)

Theoretical Analysis

MedKoo Cat#: 414718

Name: Sebetralstat HCl

CAS#: 2163789-76-0 (HCl)

Chemical Formula: C26H27ClFN5O4

Exact Mass: 491.1969

Molecular Weight: 527.98

Elemental Analysis: C, 59.15; H, 5.15; Cl, 6.71; F, 3.60; N, 13.26; O, 12.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

2163789-76-0 (HCl) 2163789-79-3 (mesylate) 1933514-13-6 (free base) 2163789-80-6 (tosylate) 2163789-82-8 (besylate)

Synonym

KVD-900, K-VD-900, Sebetralstat; Sebetralstat HCl; Sebetralstat hydrochloride;

IUPAC/Chemical Name

N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1(2H)-yl)methyl]phenyl}methyl)-1H-pyrazole-4-carboxamide hydrochloride

InChi Key

YADHGPUUDCQWKY-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H26FN5O4.ClH/c1-35-17-22-20(26(34)29-13-21-25(27)23(36-2)10-11-28-21)16-32(30-22)15-19-8-6-18(7-9-19)14-31-12-4-3-5-24(31)33;/h3-12,16H,13-15,17H2,1-2H3,(H,29,34);1H

SMILES Code

O=C(C1=CN(CC2=CC=C(CN3C=CC=CC3=O)C=C2)N=C1COC)NCC4=NC=CC(OC)=C4F.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Hereditary angioedema (HAE) is a rare genetic disorder in which patients experience sudden onset of swelling in various locations of the body. HAE is associated with uncontrolled plasma kallikrein (PKa) enzyme activity and generation of the potent inflammatory mediator, bradykinin, resulting in episodic attacks of angioedema.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 527.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Davie RL, Edwards HJ, Evans DM, Hodgson ST, Stocks MJ, Smith AJ, Rushbrooke LJ, Pethen SJ, Roe MB, Clark DE, McEwan PA, Hampton SL. Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema. J Med Chem. 2022 Oct 27;65(20):13629-13644. doi: 10.1021/acs.jmedchem.2c00921. Epub 2022 Oct 17. PMID: 36251573; PMCID: PMC9620001. 2: Mutch P, Bashir M, Jung B, Yi P, Iverson M. Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900) following a single oral dose in healthy male participants. Xenobiotica. 2022 Jul;52(7):707-717. doi: 10.1080/00498254.2022.2132187. Epub 2022 Oct 17. PMID: 36200371. 3: Duckworth EJ, Murugesan N, Li L, Rushbrooke LJ, Lee DK, De Donatis GM, Maetzel A, Yea CM, Hampton SL, Feener EP. Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema. Clin Exp Allergy. 2022 Sep;52(9):1059-1070. doi: 10.1111/cea.14122. Epub 2022 Mar 20. PMID: 35278245; PMCID: PMC9544254. 4: Maetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, Yea CM. KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results. J Allergy Clin Immunol. 2022 Jun;149(6):2034-2042. doi: 10.1016/j.jaci.2021.10.038. Epub 2022 Jan 24. PMID: 35086692.